Molecular biomarkers of sintilimab plus lenvatinib in hepatitis-B-virus-associated hepatocellular carcinoma

Figure 4 Mutational landscape and survival analysis. A: Oncoplot illustrating mutations detected by whole exome sequencing; B: Boxplots depicting comparisons of tumor mutational burden between the response group and the non-response group; C and D: Kaplan-Meier curves for survival analysis based on mutations in Fanconi anemia complementation group D2 (C) and cut-like homeobox 1 (D) within the study population; E and F: Kaplan-Meier curves for survival analysis for mutations in Fanconi anemia complementation group D2 (E) and cut-like homeobox 1 (F), utilizing data derived from The Cancer Genome Atlas. FANCD2: Fanconi anemia complementation group D2; WT: Wild type; CUX1: Cut-like homeobox 1; TCGA: The Cancer Genome Atlas; LIHC: Liver hepatocellular carcinoma.